PatientsVille.com Logo

GASTROINTESTINAL HAEMORRHAGE and Cymbalta

PatientsVille

GASTROINTESTINAL HAEMORRHAGE Symptoms and Causes

Your digestive or gastrointestinal (GI) tract includes the esophagus, stomach, small intestine, large intestine or colon, rectum, and anus. Bleeding can come from any of these areas. The amount of bleeding can be so small that only a lab test can find it.

Signs of bleeding in the digestive tract depend where it is and how much bleeding there is.

Signs of bleeding in the upper digestive tract include

  • Bright red blood in vomit
  • Vomit that looks like coffee grounds
  • Black or tarry stool
  • Dark blood mixed with stool

Signs of bleeding in the lower digestive tract include

  • Black or tarry stool
  • Dark blood mixed with stool
  • Stool mixed or coated with bright red blood

GI bleeding is not a disease, but a symptom of a disease. There are many possible causes of GI bleeding, including hemorrhoids, peptic ulcers, tears or inflammation in the esophagus, diverticulosis and diverticulitis, ulcerative colitis and Crohn's disease, colonic polyps, or cancer in the colon, stomach or esophagus.

The test used most often to look for the cause of GI bleeding is called endoscopy. It uses a flexible instrument inserted through the mouth or rectum to view the inside of the GI tract. A type of endoscopy called colonoscopy looks at the large intestine.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for GASTROINTESTINAL HAEMORRHAGE

GASTROINTESTINAL HAEMORRHAGE treatment research studies

Cymbalta clinical trials, surveys and public health registries


Find Drug Side Effect reports



Cymbalta Side Effects

Nausea (1415)
Dizziness (1321)
Headache (971)
Feeling Abnormal (918)
Fatigue (799)
Depression (787)
Insomnia (782)
Anxiety (659)
Alanine Aminotransferase Increased (646)
Hyperhidrosis (611)
Paraesthesia (610)
Diarrhoea (592)
Aspartate Aminotransferase Increased (567)
Suicidal Ideation (556)
Hepatic Enzyme Increased (518)
Blood Pressure Increased (503)
Vomiting (483)
Loss Of Consciousness (481)
Fall (476)
Asthenia (455)
Somnolence (414)
Pain (413)
Tremor (409)
Confusional State (403)
Malaise (400)
Crying (371)
Dyspnoea (339)
Agitation (326)
Hypertension (306)
Constipation (295)
Convulsion (289)
Irritability (271)
Anger (266)
Off Label Use (259)
Weight Increased (256)
Suicide Attempt (255)
Disturbance In Attention (252)
Abdominal Pain Upper (240)
Dry Mouth (237)
Chest Pain (233)
Amnesia (221)
Abdominal Pain (218)
Gamma-glutamyltransferase Increased (212)
Decreased Appetite (208)
Liver Function Test Abnormal (207)
Heart Rate Increased (206)
Death (202)
Blood Alkaline Phosphatase Increased (201)
Gait Disturbance (198)
Vision Blurred (198)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

17yrs old athlete-- been on cymbalta for about 6 mos. makes me feel very tired and weak a like I am about to pass out when I do my football workouts. I have a chance at a scholarship to play college ball but I feel so fatigued during workouts that I

Could not urinate or have bowl movement for two days. By massaging my abdomin I was able to urinate(half hour). Developed urinary tract infection. Lost 20 pounds in two weeks.Have never been suicidal in my life. After taking cymba

Has anyone experienced syptoms of Kidney stones, while taking Cymbalta, yet the Medical profession couldn't find any?

Hav been taking Cymbalta and feel great.have not had the side effects described maybe my dosage is more appropriate for my body size(i workout and keep fit)

Have there been any reports of having positive pregnancy tests while on Cymbalta but really they are not pregnant and it is a false positive

Hello has anyone had any rashes using cymbolta?

I also had Guillaine Barre Syndrome so when I started to experience side effects, and then withdrawl symptoms because of Cymbalta I was a little extra paranoid & had a tendency to (freak out) want to attribute the Cymbalta symptoms to GBS. I

I AM 45 YRS. OLD AND HAVE BEEN TAKING CYMBALTA 30 mg daily, FOR ABOUT 8 MONTHS FOR MY FIBROMAYALGIA(PAIN EVERYWHERE) I LOST 10 POUNDS IN THE FIRST TWO WEEKS AND FELT SOME RELIEF.AT A ABOUT A MONTH LATER MY PAIN WAS WORSE AND MY VISION HAS BLURRED, I

I am currently on Lyrica and my doctor added Cymbalta. Since starting the Cymbalta I have become depressed. Has anyone else experienced this?

I am having breathing problems and now have basiliar interstitial prominence. If I stop the cymbalta will these problems go away? I am scared

Actuallly the risk of a gastrointestinal bleeding is increased with Pradaxa compared to Warfarin, there isalso an interaction withVerapamil leading to higher plama levels of Pradaxa.

Gastrointestinal. Severe pain starting in middle of chest and wrapping around to middle of back. Tests showed inflamation in stomach and I am now on a bland diet indefinately. Also had trouble swallowing pills and food.&

Hi! Some years ago I took nexium for v. severe gerd, with haemorrhage. From the time I started it, suddenly my gastric system was totally upset, where it hadn't previously. Because I wasn't digesting properly, my immune system was affected, and hav

I am currently involve in a case study about hypercholesterilemia, our patient was given Niacin and Cholestyramine resin(Questran) it was stop because the patient cannot tolerate the flushing and gastrointestinal effects bought by this drugs and repl

I had funny gastrointestinal feelings. Almost as if balloons were popping in my stomach. I had the urge to stool but only the flatulence sound---no stools. I always felt so 'empty' even though I was eating regularly. I stopped at three days I couldn'

I have had Aclasta infusions twice now. On both occasions I experienced gastrointestinal symptoms but three weeks later. One time, it was very acute, right lower quadrant pain, and this year it has been cramps and diarrhea. First time, I felt unwell

I received a dose on May 12 and May 13, 2010 that Friday on May16 i got a really violent headache. By Saturday, I ended up with terrible sweating, fatigue, gastrointestinal problems. On Sunday more of the same. Monday st

I take Vastarel MR once a day. Tired, gastrointestinal increase

I was diagnosed with diabetes 2 years ago and have been taking one diabex xr tablet per day with dinner . Since then I have had gastrointestinal problems which only ease with gastro stop tabletswhen needed. I am frightened to goan

I was diagnosed with diabetes 2 years ago. I take one tablet a day with dinner, Since taking diabex I have cramps, and diarrea and gastrointestinal problems . My life is becoming a series of toilet seeking on journeys and I hate travelling. Could thi

GASTROINTESTINAL HAEMORRHAGE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting The Cymbalta Pregnancy Registry
Condition: Pregnancy
Intervention: Drug: duloxetine
Outcome Measures: To estimate the risk of major congenital anomalies among pregnancies exposed to Cymbalta;   To estimate risk of recognized spontaneous abortions, stillbirths, elective terminations, minor congenital anomalies, and any serious adverse pregnancy outcomes among pregnancies exposed to Cymbalta and their live births during the first year of life;   To examine any potential impact of Cymbalta use while breastfeeding on the infant during the first year of life;   To compare the risk of major congenital anomalies among pregnancies exposed to Cymbalta to an appropriate comparator(s) such as the Centers for Disease Control and Prevention (CDC) Metropolitan Atlanta Congenital Defects Program (MACDP)
2 Unknown  Cymbalta for Fibromyalgia Pain
Condition: Fibromyalgia
Intervention: Drug: Duloxetine
Outcome Measures: Nerve Histology;   Improved Pain Ratings
3 Recruiting Crossover Trial of Duloxetine Versus Placebo in Breast Cancer Patients With Chronic Pain
Condition: Pain
Interventions: Drug: Duloxetine;   Drug: Placebo
Outcome Measures: Change in patient-reported pain between baseline and 6 weeks of treatment with duloxetine versus placebo;   Change in objectively assessed pain sensitivity between baseline and 6 weeks of treatment with duloxetine versus placebo
4 Unknown  Duloxetine for Major Depression in Peri-/Postmenopausal Women
Condition: Major Depressive Disorder
Intervention: Drug: Duloxetine
Outcome Measures: The effects of response to treatment with duloxetine on brain structure and activation in subjects (peri- and postmenopausal women with MDD).;   Changes in brain activation in remitters versus non-remitters after treatment with duloxetine (remission of depression defined MADRS total score <10 at study end).;   Correlations between changes in brain activation and changes from baseline to study end and menopausal symptoms, depressive symptoms, cognition, quality of life, and clinical global impression (improvement and severity).
5 Recruiting Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component
Condition: Chronic Low Back Pain
Intervention: Drug: Duloxetine
Outcome Measures: Weekly mean pain intensity in study phase I (Visual analogue score, units 1-10);   Weekly mean pain intensity in study phase II (Visual analogue score, units 1-10);   Use of rescue medication in study phase I;   Beck Depression Inventory score in phase I of study period;   Health related Quality of Life SF-36 score in phase I of study period;   painDetect score in phase I of study period;   Use of rescue medication in phase II of study period;   Beck Depression Inventory score in phase II of study period;   Health related Quality of Life SF-36 score in phase II of study period.;   painDetect score in phase II of study period
6 Unknown  Study to Assess Mechanisms in Peripheral Tissue Innervation for Fibromyalgia
Condition: Fibromyalgia
Interventions: Drug: Duloxetine;   Procedure: Skin biopsy
Outcome Measure: Efficacy of duloxetine will be determined by neurological and pain assessments.
7 Unknown  Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder
Condition: Posttraumatic Stress Disorders
Intervention: Drug: Duloxetine hydrochloride
Outcome Measures: PTSD Symptoms will be assessed by the Clinician-Administered PTSD Scale for DSM-IV (CAPS);   Visual Analog Scale for Pain (VAS)
8 Recruiting Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?
Condition: Total Knee Arthroplasty
Interventions: Drug: Placebo;   Drug: Duloxetine 60mg
Outcome Measures: NRS Pain with ambulation at 2 weeks;   Numeric Rating Scale (NRS) Pain Scores at Rest, during Ambulation and while Bending Knee
9 Recruiting An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
Condition: Back Pain Lower Back Chronic
Intervention: Drug: Duloxetine
Outcome Measures: Number of Participants with Drug Related Adverse Events (AEs) or any Serious AE's;   Change from Baseline in Brief Pain Inventory (BPI) Pain Severity Item and Interference Item to Week 50;   Patient Global Impression of Improvement (PGI-Improvement) to Week 50;   Change from Baseline in Clinical Global Impression of Severity (CGI-Severity) to Week 50;   Change from Baseline in Roland Morris Disability Questionnaire (RMDQ-24) to Week 50;   Change from Baseline in 36-Item Short-Form Health Survey (SF-36) to Week 50;   Change from Baseline in European Quality of Life Questionnaire-5 Dimension (EQ-5D) to Week 50;   Change from Baseline in Beck Depression Inventory-II (BDI-II) to Week 50;   Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) to Week 52;   Number of Participants with Fall Events from Fall Questionnaire
10 Recruiting Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)
Condition: Obsessive Compulsive Disorder
Intervention: Drug: Duloxetine
Outcome Measures: Y-BOCS scores at 1st and last visit (17 weeks later);   BDI - first and last visit (Given week 0, 1, 5, 9, 13, & 17);   BAI - first and last visit (Given week 0, 1, 5, 9, 13, & 17);   QLESQ - first and last visit (Given week 0 and 17);   Clinical Global Impressions Scale at 2nd visit (2 weeks after 1st visit) and 6th visit (17 weeks post first visit)
11 Recruiting Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
Conditions: Major Depression;   Irritable Bowel Syndrome Symptoms
Intervention: Drug: Duloxetine
Outcome Measures: Montgomery-Asberg Depression Rating Scale (MADRS);   Gastrointestinal Symptoms Rating Scale (GSRS);   Clinician-Rated Global Impression Scales;   Visual Analogue Scales (VAS);   Somatization module of the Patient's Health Questionnaire (PHQ-15)
12 Recruiting A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China
Condition: Osteoarthritis
Interventions: Drug: Duloxetine;   Drug: Placebo
Outcome Measures: Change from Baseline to 13 Weeks in the Brief Pain Inventory (BPI) 24-hour Average Pain Rating;   Patient Global Impressions of Improvement (PGI-I) at 13 Weeks;   Change from Baseline to 13 Weeks in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total and Subscale Scores;   Change from Baseline to 13 Weeks in Clinical Global Impression of Severity (CGI-S);   Change from Baseline to 13 Weeks in BPI Severity;   Change from Baseline to 13 Weeks in Hospital Anxiety and Depression Scale-Depression (HADS-D) or HADS-Anxiety (HADS-A) Subscale Scores
13 Recruiting A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
Condition: Fibromyalgia
Interventions: Drug: Duloxetine;   Drug: Placebo
Outcome Measures: Change from baseline to 13 week endpoint in Brief Pain Inventory (BPI) modified short form-adolescent version 24 hour average pain severity item;   Change from baseline to 13 week endpoint in Brief Pain Inventory (BPI) modified short form-adolescent version severity and interference items;   Maintenance effect in acute phase responders on the Brief Pain Inventory (BPI) modified short form-adolescent version 24 hour average pain severity item;   Proportion of patients with greater than or equal to 30% and 50% reduction in BPI 24 hour average pain severity score at 13 weeks;   Change from baseline in Pediatric Pain Questionnaire (PPQ) item scores;   Change from baseline in Clinical Global Impression (CGI) Severity: overall score and mental illness score;   Change from baseline in Functional Disability Inventory (FDI) child scale and rent scale;   Change from baseline in Children's Depression Inventory (CDI);   Change from baseline in Multidimensional Anxiety Scale for Children (MASC)
14 Recruiting Duloxetine Versus Pregabalin for Alcohol Dependence
Condition: Alcohol Dependence
Interventions: Drug: Pregabalin;   Drug: Duloxetine;   Behavioral: Standardized behavioral therapy;   Drug: Placebo
Outcome Measure: Drinking Quantity and Frequency
15 Recruiting Duloxetine for the Treatment of Chronic Pelvic Pain
Condition: Pelvis Pain Chronic
Interventions: Drug: Duloxetine;   Drug: Sugar Pill
Outcome Measures: The primary clinical efficacy measure is reduction in spontaneous (non-evoked) pelvic pain. This will be assessed by using the 0-10 numerical pain ratings to derive the primary outcome variable of clinical pain intensity difference due to treatment.;   Functional limitations due to pain
16 Unknown  Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients
Conditions: Diabetes;   Painful Neuropathy
Intervention: Drug: Duloxetine
Outcome Measures: Prediction of duloxetine pain relief efficacy by pre-treatment extent of the CPM response;   Treatment-related increase in CPM response
17 Unknown  Effects of Duloxetine on Fear Conditioning in Posttraumatic Stress Disorder (PTSD)
Condition: Posttraumatic Stress Disorder
Intervention: Drug: Duloxetine
Outcome Measure: Anxiolytic and antidepressant effects of duloxetine in patients with chronic PTSD
18 Not yet recruiting Research Examining Gulf War Illness in Our Nations Service Members
Condition: Gulf War Illness
Interventions: Drug: Duloxetine;   Drug: Pregabalin;   Drug: Placebo
Outcome Measures: Pain , Safety, tolerability;   Side Effects
19 Not yet recruiting Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Duloxetine;   Drug: placebo;   Other: Study visits only
Outcome Measures: >= 50% improvement in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (MADRS Response);   MADRS remission;   Credibility and Expectancy Scale (CES)
20 Recruiting S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Conditions: Breast Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: duloxetine hydrochloride;   Other: placebo
Outcome Measures: Reduction in average joint pain according to BPI-SF assessed up to 12 weeks;   Reduction in worst joint pain according to the BPI-SF worst pain score assessed up to 12 weeks;   Reduction in pain interference according to the BPI-SF worst pain score assessed up to 12 weeks